COMMUNIQUÉS West-GlobeNewswire
-
Evosep Launches IQ/OQ Protocols for the Evosep Eno System at WCBP 2026
27/01/2026 -
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
27/01/2026 -
Science 37 Appoints Kelly Johnston McKee as VP of Strategy & Transformation
27/01/2026 -
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
27/01/2026 -
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
27/01/2026 -
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
27/01/2026 -
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
27/01/2026 -
PreatLoc™ by Preat® is Now Available
27/01/2026 -
Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Functional Beverage Distribution Across Canada Through Walmart Canada and McKesson Canada
27/01/2026 -
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
27/01/2026 -
First Steroid Cycle for Bodybuilders – CrazyBulk | Steroids for Beginners Bulking and Cutting: Safest Steroids for Bodybuilding
27/01/2026 -
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
27/01/2026 -
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
27/01/2026 -
Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned
27/01/2026 -
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
27/01/2026 -
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
27/01/2026 -
Acentra Health Appoints Balajee Sethuraman as Executive Vice President and Chief Business Services Officer
27/01/2026 -
ABLi Therapeutics Completes Collaboration Agreement with The Michael J. Fox Foundation to include Risvodetinib in Path to Prevention Platform Trial
27/01/2026 -
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
27/01/2026
Pages